千紅製藥(002550.SZ):擬與牧原股份成立合資公司 進一步拓展公司肝素產業鏈
格隆匯1月6日丨千紅製藥(002550.SZ)公佈,公司將與牧原股份(002714.SZ)簽署《常州千紅生化製藥股份有限公司和牧原食品股份有限公司之合資協議》,並共同投資成立合資公司“河南千牧生物科技有限公司”(暫定名,具體名稱以市場監督管理部門最終核定為準,簡稱“合資公司”或“河南千牧”)。
河南千牧註冊資本人民幣1億元整,其中:千紅製藥(或其控股子公司)以現金方式出資5100萬元,佔註冊資本51.00%;牧原股份(或其控股子公司)以現金方式出資4900萬元,佔註冊資本的49.00%。河南千牧成立後,為公司控股子公司。
合資公司的經營宗旨為建設全球規模領先的豬小腸等豬副產品綜合利用及生物製藥基地,並以此為核心帶動南陽市生物醫藥產業發展,打造國內先進的生物醫藥產業園區。
公司表示,此次與牧原股份成立合資公司,有利於依託牧原股份國內生豬養殖與屠宰的資源優勢,並結合公司在肝素鈉粗品和肝素原料藥、製劑領域的專業生產技術、質量管理等經驗,建設全球規模及溯源性領先的豬小腸等豬副產品綜合利用生物製藥基地,生產包含但不限於肝素鈉粗品、肝素鈉及低分子肝素鈉系列原料藥及製劑等相關產品。進一步拓展公司肝素產業鏈,做大經營規模,增強核心競爭力,對公司未來持續穩定發展具有積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.